RECURRENT PLASMA CELL MYELOMA

This study tests a combination of standard chemotherapy (bortezomib, dexamethasone), an immunotherapy (pembrolizumab), and a lab-modified virus (pelareorep) in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to see if adding the viru…

This study tests a specific timing of chemotherapy drugs (busulfan, fludarabine, and cyclophosphamide) before and after a donor stem cell transplant in 204 people with various blood cancers. The goal is to reduce the risk of the transplant failing or causing severe side effects l…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in 5 adults with multiple myeloma that has come back or is not responding to standard treatments. The goal is to see how many patients' tumors shrink significantly. This is not a cure, but a…

This study tests a two-step treatment plan for people with multiple myeloma that has come back or stopped responding to therapy. First, patients receive a combination of daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal …

This early-phase trial tests a personalized therapy where a patient's own T-cells are trained to recognize and attack the MUC1 protein on myeloma cells. The study enrolls 5 adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. Th…

This study looks at how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and loss of appetite) and the emotional toll it takes on both patients and their primary caregivers. Researchers will track weight changes and use questionnair…